TSH 0.31 on Levothyroxine 88mcg: Dose Adjustment
You should reduce your levothyroxine dose by 12.5-25 mcg (to either 75 mcg or 62.5 mcg daily) because your TSH of 0.31 mIU/L indicates overtreatment, which carries cardiovascular and skeletal risks. 1
Why This Matters
Your TSH is below the normal reference range (typically 0.4-4.12 mIU/L), indicating you're receiving too much thyroid hormone replacement. This is not a trivial issue—overtreatment with levothyroxine has been documented in 20% of treated patients and carries significant adverse consequences 1:
- Cardiovascular risks: atrial fibrillation (especially in elderly patients), increased heart rate, and coronary insufficiency
- Skeletal risks: accelerated bone loss and osteoporotic fractures (particularly in postmenopausal women)
- Neuropsychiatric effects: possible affective disturbances
The Dosing Algorithm
Step 1: Confirm Overtreatment
Your TSH of 0.31 mIU/L is below 0.4 mIU/L, confirming overtreatment. The guidelines are clear that the most reliable therapeutic endpoint for primary hypothyroidism is the serum TSH value 1. While some debate exists about optimal TSH targets (with some suggesting 2.5-3.0 mIU/L as upper normal), there's no controversy that TSH below 0.4 mIU/L represents overtreatment.
Step 2: Reduce Dose Appropriately
Make increment changes of 12.5-25 mcg/day 1. Given your current dose of 88 mcg:
- Reduce to 75 mcg daily (13 mcg reduction), OR
- Reduce to 62.5 mcg daily (25.5 mcg reduction) if more aggressive correction needed
The FDA labeling confirms this approach, stating dose adjustments should be made and TSH monitored every 6-8 weeks after any dosage change 2.
Step 3: Recheck TSH in 6-8 Weeks
Do not recheck sooner than 4-8 weeks 1. This timing is critical because:
- Levothyroxine has a long half-life
- TSH levels take time to plateau after dose adjustments
- Premature testing leads to unnecessary dose changes
The guidelines emphasize that tests should be performed at least every 4-8 weeks until stable euthyroid indices have been documented 1.
Step 4: Target TSH Range
Aim for TSH in the normal reference range (0.4-4.12 mIU/L). The evidence does not support targeting specific TSH values within the normal reference range for non-pregnant patients 1. A TSH between 1-2 mIU/L is often considered optimal, but anywhere in the normal range is acceptable.
Important Considerations
Check for Absorption Issues
Before assuming you need a lower dose, verify you're taking levothyroxine correctly:
- Take with water 30-60 minutes before breakfast OR at bedtime 4 hours after the last meal 1
- Avoid taking with substances that interfere with absorption: iron, calcium, soy, fiber, grapefruit juice 2
- Ensure proper storage at room temperature, protected from light and moisture 1
Age and Weight Factors
Levothyroxine requirements decrease with age 1. Elderly patients often require 20-25% less per kilogram than younger patients due to decreased lean body mass. If you've experienced significant weight loss, this could also explain why your current dose is now excessive.
Medication Interactions
Review any new medications started since your dose was stable. Certain drugs can alter levothyroxine metabolism or absorption, potentially making your current dose excessive 1.
Common Pitfalls to Avoid
Don't ignore subclinical overtreatment: Even a "slight" overdose carries real risks, particularly for cardiovascular and bone health 1
Don't adjust doses too frequently: Wait the full 6-8 weeks between dose changes to allow TSH to stabilize 2
Don't assume compliance issues first: While non-compliance is common with high TSH, your low TSH suggests genuine overtreatment rather than missed doses 1
Don't make tiny adjustments: The standard increment is 12.5-25 mcg, not 5-10 mcg changes 1
Follow-Up Plan
After dose reduction:
- Recheck TSH in 6-8 weeks 2
- Once stable in normal range, monitor every 6-12 months 1
- Report any symptoms of hypothyroidism (fatigue, cold intolerance, weight gain) or continued hyperthyroidism (palpitations, tremor, anxiety)
The goal is to maintain you in a euthyroid state without the adverse cardiovascular and skeletal consequences of chronic overtreatment.